Compugen Sells Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
I'm PortAI, I can summarize articles.
Compugen Ltd. amended its license agreement with AstraZeneca, selling a portion of future royalties for rilvegostomig. Compugen will receive $65 million upfront and potentially $25 million more upon milestone achievement, totaling up to $90 million. The deal aims to extend Compugen's cash runway into 2029 and support its immuno-oncology pipeline. Compugen retains majority future royalties and eligibility for tiered royalties and milestone payments up to $195 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments